Please tell us about your clinical experience. How many patients get the Hepatitis B vaccine yearly under your supervision? What are the most commonly used vaccines, and what are their safety and efficacy profiles in comparison to one another?

In November 2017, Heplisav-B (Dynavax) two-dose vaccine was approved for use in adults aged 18 and older. What is the profile of the patients who are at risk for hepatitis b?

On Nov 3 2021, CDC’s ACIP unanimously passed a universal HBV vaccination recommendation for all adults age 19-59, and for adults age 60+ with risk factors for infection. What percent of the doctors do you think will recommend adult patients to take the vaccine, and what would the immunization rate look like?

What % of the adults with hepatitis B recover fully? How many have severe signs and symptoms?

Can you walk us through the increased risks of infants and children more likely to develop a chronic hepatitis B infection? Can you see VBIV's vaccine working in the pediatric setting as well?

How often does Hepatitis B become chronic and require lifelong management? What treatment choice do those patients have?

What’s your impression on VBIV’s Prophylactic indication for its vaccine?

Can you tell us more about the S, pre-S1, and pre-S2 surface antigens of the hepatitis B virus? How does VBIV’s vaccine stand out from the others?

What do you think about the AE profile of VBIV’s vaccine, compared to ENGERIX-B for example?